Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein
Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar
Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search.
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with China, FDA Commissioner Marty Makary said.
The FDA has to …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844